Similar articles

• Letter by Wang et al Regarding Article, "Legumain Is an Endogenous Modulator of Integrin αvβ3 Triggering Vascular Degeneration, Dissection, and Rupture".

  Wang D, Ma Z, Wang T. Wang D, et al. Circulation. 2022 Sep 13;146(11):e142-e143. doi: 10.1161/CIRCULATIONAHA.122.060398. Epub 2022 Sep 12. Circulation. 2022. PMID: 36095060 No abstract available.
• Legumain Is an Endogenous Modulator of Integrin αvβ3 Triggering Vascular Degeneration, Dissection, and Rupture.

  Pan L, Bai P, Weng X, Liu J, Chen Y, Chen S, Ma X, Hu K, Sun A, Ge J. Pan L, et al. Circulation. 2022 Mar;145(9):659-674. doi: 10.1161/CIRCULATIONAHA.121.056640. Epub 2022 Jan 31. Circulation. 2022. PMID: 35100526
• Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.

  Liu Y, Goswami RK, Liu C, Sinha SC. Liu Y, et al. Mol Pharm. 2015 Jul 6;12(7):2544-50. doi: 10.1021/acs.molpharmaceut.5b00257. Epub 2015 Jun 9. Mol Pharm. 2015. PMID: 26024761 Free PMC article.
• Activated alphavbeta3 integrin targeting in injury-induced vascular remodeling.

  Sadeghi MM, Bender JR. Sadeghi MM, et al. Trends Cardiovasc Med. 2007 Jan;17(1):5-10. doi: 10.1016/j.tcm.2006.07.003. Trends Cardiovasc Med. 2007. PMID: 17210471 Review.
• Vitronectin receptors in vascular disorders.

  Mousa SA. Mousa SA. Curr Opin Investig Drugs. 2002 Aug;3(8):1191-5. Curr Opin Investig Drugs. 2002. PMID: 12211413 Review.